NEW YORK, May 2, 2017 /PRNewswire/ -- According
Post# of 15624
(Total Views: 373)
Posted On: 05/02/2017 9:45:14 AM
NEW YORK, May 2, 2017 /PRNewswire/ --
According to a research conducted by Hemp Business Journal and Vote Hemp, the Hemp CBD is a market with $130 million in sales with growth at a 53% AGR (Adjusted Growth Revenue). This as a result contributed to the $688 million in total Hemp sales in 2016. The Hemp CBD category was led by channel sales in natural and specialty products such as smoke shops and online verticals. As well in 2016, SPINS, the leading market research firm for natural products, has listed that $2,470,000 worth of products has used CBD as a primary ingredient. Currently CBD-based pet care products are a 'growth category to watch' in 2017. ChineseInvestors.com, Inc. (OTC: CIIX), AXIM Biotechnologies, Inc. (OTC: AXIM), Mentor Capital Inc. (OTC: MNTR), OWC Pharmaceutical Research Corp. (OTCQB: OWCP), MassRoots Inc. (OTCQB: MSRT).
Eric Steenstra, President of Vote Hemp has referenced, "To date, 31 states have passed legislation that allows hemp farming per provisions set forth in the 2014 Farm Bill, and the U.S. remains the largest consumer market for hemp products worldwide. We need Congress to pass federal legislation to allow commercial hemp farming nationally, to let our farmers and American businesses take advantage of the robust economic opportunity hemp provides."
ChineseInvestors.com, Inc. (OTCQB: CIIX) just announced this morning that it has appointed Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly owned foreign entity, CBD Biotechnology Co. Ltd. ("XiBiDi Biotech"
. XiBiDi Biotech's primary focus is online, retail and direct sales of hemp-based health products in China. Yun's initial focus will be the launch of 'CBD Magic Hemp Series' cosmetics line. He will also spearhead the Company's plan to import natural dietary supplements created using advanced extracting and purifying technologies into China. Yun is a marketing and branding executive with over 25 years of experience. Yun will report directly to CIIX's CEO Warren Wang.
"I am honored to be named as CEO of CBD Biotech," says Yun. "For over 5,000 years, hemp has been cultivated and used in over 25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care products in China online and through established retail and direct selling channels. Through the introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding hemp's many benefits."
"I believe Yun is the perfect candidate to oversee CBD Biotech's operations. I am confident in his ability to introduce this revolutionary CBD-based skin care line to China and create and generate substantial revenue for CIIX," says Wang.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. On March 07, the company announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company's CanChew Plus® CBD gum. Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.
Mentor Capital Inc. (OTCQB: MNTR) seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives to add protection for investors and to help incubate private cannabis companies. Recently, the company announced it has again provided $100,000 in special project financing for cannabis advisory leader Electrum Partners, LLC. Mentor CEO Billingsley said, "We refer to the larger medical marijuana and cannabis companies that we are helping to efficiently move into the public market as core holdings and segregate these into a major pure play pool. We at Mentor certainly see Electrum Partners as a great pending candidate for us to work with in this regard."
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), recently announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announced positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. OWCP's scientific team, led by the renowned Dr. Yehuda Baruch, the Company's Chief Science Officer and OWC's Director of Research and Regulatory Affairs, and former Director of Israel's Ministry of Health Medical Management Division, previously reported trial results and concluded that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis.
MassRoots Inc. (OTCQB: MSRT) is one of the leading technology platforms for the regulated cannabis industry. The company's mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. On March 27, 2017, the company announced it has launched a new website. Powered by more than one million registered users, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., effectiveness for treating ailments such as back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary.
According to a research conducted by Hemp Business Journal and Vote Hemp, the Hemp CBD is a market with $130 million in sales with growth at a 53% AGR (Adjusted Growth Revenue). This as a result contributed to the $688 million in total Hemp sales in 2016. The Hemp CBD category was led by channel sales in natural and specialty products such as smoke shops and online verticals. As well in 2016, SPINS, the leading market research firm for natural products, has listed that $2,470,000 worth of products has used CBD as a primary ingredient. Currently CBD-based pet care products are a 'growth category to watch' in 2017. ChineseInvestors.com, Inc. (OTC: CIIX), AXIM Biotechnologies, Inc. (OTC: AXIM), Mentor Capital Inc. (OTC: MNTR), OWC Pharmaceutical Research Corp. (OTCQB: OWCP), MassRoots Inc. (OTCQB: MSRT).
Eric Steenstra, President of Vote Hemp has referenced, "To date, 31 states have passed legislation that allows hemp farming per provisions set forth in the 2014 Farm Bill, and the U.S. remains the largest consumer market for hemp products worldwide. We need Congress to pass federal legislation to allow commercial hemp farming nationally, to let our farmers and American businesses take advantage of the robust economic opportunity hemp provides."
ChineseInvestors.com, Inc. (OTCQB: CIIX) just announced this morning that it has appointed Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly owned foreign entity, CBD Biotechnology Co. Ltd. ("XiBiDi Biotech"
. XiBiDi Biotech's primary focus is online, retail and direct sales of hemp-based health products in China. Yun's initial focus will be the launch of 'CBD Magic Hemp Series' cosmetics line. He will also spearhead the Company's plan to import natural dietary supplements created using advanced extracting and purifying technologies into China. Yun is a marketing and branding executive with over 25 years of experience. Yun will report directly to CIIX's CEO Warren Wang. "I am honored to be named as CEO of CBD Biotech," says Yun. "For over 5,000 years, hemp has been cultivated and used in over 25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care products in China online and through established retail and direct selling channels. Through the introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding hemp's many benefits."
"I believe Yun is the perfect candidate to oversee CBD Biotech's operations. I am confident in his ability to introduce this revolutionary CBD-based skin care line to China and create and generate substantial revenue for CIIX," says Wang.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. On March 07, the company announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company's CanChew Plus® CBD gum. Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.
Mentor Capital Inc. (OTCQB: MNTR) seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives to add protection for investors and to help incubate private cannabis companies. Recently, the company announced it has again provided $100,000 in special project financing for cannabis advisory leader Electrum Partners, LLC. Mentor CEO Billingsley said, "We refer to the larger medical marijuana and cannabis companies that we are helping to efficiently move into the public market as core holdings and segregate these into a major pure play pool. We at Mentor certainly see Electrum Partners as a great pending candidate for us to work with in this regard."
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), recently announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announced positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. OWCP's scientific team, led by the renowned Dr. Yehuda Baruch, the Company's Chief Science Officer and OWC's Director of Research and Regulatory Affairs, and former Director of Israel's Ministry of Health Medical Management Division, previously reported trial results and concluded that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis.
MassRoots Inc. (OTCQB: MSRT) is one of the leading technology platforms for the regulated cannabis industry. The company's mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. On March 27, 2017, the company announced it has launched a new website. Powered by more than one million registered users, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., effectiveness for treating ailments such as back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary.
(3)
(0)